Novo Integrated Sciences, Inc (NVOS) Fair Value & Analysis
Healthcare · US · Market cap $13.8K
Novo Integrated Sciences, Inc
NVOS · US
Fair value as of: Jun 26, 2026
From 1 valuation models · updated 7 days ago
Fair value updated Jun 26, 2026 — revised from $3.40 to $0.0038 (−99.9%) since Jun 24, 2026. Share price −82.5% over the past month.
Price vs Fair Value (12 months)
12‑month range $0.0001 – $0.0669 · fair‑value band $0.0038 – $0.0038 · the $0.0039 price screens above the $0.0038 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Novo Integrated Sciences, Inc (NVOS) currently trades at $0.0039, while our model-based Fair Value estimate is $0.0038 — implying the stock looks roughly 3.3% overvalued today. We read business quality at 37/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at $13.3M. Revenue declined 6.7% year over year. It earns a return on equity of -82.5%. Net debt stands at $3.9M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Novo Integrated Sciences, Inc., together with its subsidiaries, provides multidisciplinary primary care and related wellness products and services in Canada. It operates in two segments, Healthcare Services and Product Sales. The company offers physiotherapy, chiropractic care, manual/manipulative therapy, occupational therapy, eldercare, massage therapy, acupuncture and functional dry needling, chiropody, stroke and traumatic brain injury/neurological rehabilitation, kinesiology, vestibular therapy, concussion management and baseline testing, trauma sensitive yoga and meditation for concussion-acquired brain injury and occupational stress-PTSD, women's pelvic health programs, sports medicine therapy, assistive devices, dietitian, holistic nutrition, fall prevention education, sports team conditioning programs, including event and game coverage, and private personal training services through clinics. It also provides assessment, diagnosis, treatment, pain management, …
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
Novo Integrated Sciences, Inc reported revenue of $13.3M in FY2024 versus $7.9M in FY2020, a compound +14.0%/yr. Reported net income was −$16.1M in FY2024.
Is NVOS fairly valued? → Check now
Similar stocks
6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$96.00 | R$25.67 | -73% |
| Fresenius SE FSNUY | $11.30 | $8.61 | -24% |
| Q0F Q0F | 2.76 SGD | 1.28 SGD | -54% |
| 5225 5225 | 8.67 MYR | 3.08 MYR | -64% |
| IHHHF IHHHF | $1.71 | $0.7400 | -57% |
| Rede D'Or São Luiz S.A RDOR3 | R$32.76 | R$30.33 | -7% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Novo Integrated Sciences, Inc (NVOS) undervalued?
What is the fair value of NVOS?
What is the quality score of NVOS?
What is the revenue of Novo Integrated Sciences, Inc (NVOS)?
What is the net profit margin of NVOS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.